Form 4: Jazz Pharmaceuticals CEO Bruce Cozadd Sells 1,000 Shares
SEC Form 4
Bruce Cozadd, Chairman and CEO of Jazz Pharmaceuticals, sold 1,000 ordinary shares at a price of $110.84 on November 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On November 1, 2024, Bruce C. Cozadd, the Chairman and CEO of Jazz Pharmaceuticals plc, sold 1,000 ordinary shares of the company.
- The sale was executed at a price of $110.84 per share.
- This transaction was conducted under a pre-existing Rule 10b5-1 trading plan.
- Following the transaction, Cozadd directly owns 428,976 ordinary shares, which includes 167 shares acquired on May 31, 2024, through an Employee Stock Purchase Plan.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction was executed under a pre-arranged trading plan and doesn't necessarily reflect a change in the executive's outlook on the company.
Industry Context
Insider sales are a common occurrence and are often scrutinized by investors as they can provide insights into management's perspective on the company's valuation and future prospects. However, sales under a pre-arranged 10b5-1 trading plan are less likely to be indicative of management's current sentiment, as these plans are established in advance.
Key Dates
| Date | Description |
|---|---|
| May 31, 2024 | Bruce Cozadd acquired 167 ordinary shares under a Section 423 Employee Stock Purchase Plan. |
| November 01, 2024 | Bruce Cozadd sold 1,000 ordinary shares at $110.84 per share. |
| November 05, 2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.